ESMO believes that the definition and use of clinical practice guidelines (CPG) to inform medical decisions in oncology will be important for the quality of care of cancer patients. Thus, guidelines will be important for the future development of medical oncology in Europe as a specialty and, consequently, can be important in achieving high common standards of medical practice for cancer patients.
The need for clinical guidelines has been discussed within ESMO by two forums: the Central Eastern European Task Force and the National Representatives Committee. The Central Eastern European Task Force was established by ESMO to promote the development of medical oncology in the countries of Central and Eastern Europe. Two priorities have emerged from this Task Force: the need for an educational programme, and the need for clinical practice guidelines both to assist medical oncologists in their daily clinical decisions and to support negotiations with politicians, administrators, insurance companies, etc. The National Representatives Committee noted that medical oncology is at different levels in different countries. Representatives of several countries outside the Central Eastern European Task force also identified guidelines to be important to promote medical oncology and to be able to provide adequate care for patients with cancer.
Based on these considerations the ESMO Guidelines Task Force was established in 1998 and met for the first time in February 1999. A number of key decisions were made at that first meeting; specifically, ESMO guidelines should start from clinical questions, be patientcentered and evidence-based. Moreover, given the cost of CPG development and the work that various groups have already done in this field, it would not be justified to generate completely new guidelines from original data. The Task Force proposed that ESMO would produce Minimum Clinical Recommendations based on already existing CPG. They are intended to provide the user with a set of statements for a basic standard of care that ESMO would feel necessary in all countries of Europe.
The influence of local circumstances, the cultural and organisational context of the health care system on the formulation of CPG highlight the importance of the identification of minimal common standards.
As a first step, the Task Force realized a survey among the ESMO National Representatives regarding national guidelines in oncology throughout Europe. This survey showed an important heterogeneity of the development, organization and funding of CPG programmes in the different countries. Some countries have well funded and well established programmes of guidelines throughout oncology for example the Swiss Society of Medical Oncology, the French Education of Comprehensive Cancer centers (the Standards, Options and Recommendations) while others had not begun to address the issue. These initiatives provide the basis for the development of Minimal Clinical Recommendations and the opportunity to avoid the duplication of effort.
For the first series of recommendations, the Task Force chose a number of important disease entities as well as some key issues in supportive care: cancer of unknown primary origin (CUP), lymphoma, colorectal cancer, breast cancer, testicular cancer, lung cancer, ovarian cancer, large cell lymphoma, anti-emetics, pain management, and growth factors. A standard outline for the Minimum Clinical Recommendations was drafted by the Task Force based on the guidelines of the Swiss Society for Medical Oncology. Each recommendation, or set of related recommendations, was assigned to a coordinator chosen by the Task Force. To expedite the process and broaden involvement of guideline users in the project, it was decided that these coordinators should be younger medical oncologists. During the ECCO meeting in Vienna in September 1999, potential coordinators were provided with the relevant information on methodology and procedures. The response from prospective coordinators to the invitations was encouragingly positive and first drafts were received from all invited coordinators in time. The received drafts and the revisions of the coordinators were reviewed by the Task Force twice during the last year, centrally edited to the proper format by the central coordinator before being submitted to the ESMO Faculty for review. Comments from the Faculty were again considered by the Task Force before preparing the final versions. The coordinators were informed of the final changes and where appropriate their final comments were included. During the ESMO meeting in Hamburg in October 2000, Minimum Clinical Recommendations on lung cancer, testicular cancer and colon cancer were presented by the responsible coordinator and discussed by a member of the ESMO Faculty.
The process of establishing ESMO Minimum Clinical Recommendations has been very successful. It took just over one year to achieve our initial goal. The ESMO Minimum Clinical Recommendations now available do represent the beginning of a process. Their content is a reflection on the judgement of evidence published in print up to last year. The Minimum Clinical Recommendations will be updated yearly by the Guidelines Task Force with the help of the coordinators. Individual members of the Guidelines Task Force have been assigned the upkeep of certain Minimum Clinical Recommendations. In addition, ESMO members are invited to use and to discuss the Minimum Clinical Recommendations on the national, regional and local level and to send specific comments or suggestions to the ESMO Guidelines Task Force for consideration.
As the ESMO Minimal Clinical Recommendations should be a useful tool to inform clinical decisions, guideline implementation and update are major challenges. For the established recommendations, a programme of distribution and promotion by the ESMO National Representatives must be developed. To facilitate access to the information, the ESMO Minimum Clinical Recommendations will be translated by several national organizations. The Guidelines Task Force has selected further disease entities and issues in supportive care for Minimum Clinical Recommendations. Dissemination and discussion at national level will be an important step for the successful implementation of minimal standards in oncology throughout Europe. Hopefully, the experience gathered in the early days of the Task Force can be brought to bear on the speed of the development of the new recommendations. In the long term we hope that the expertise now developed by ESMO will promote collaboration with other disciplines, which may lead to multidisciplinary recommendations and so achieve our ultimate goal of high common standards of medical practice for cancer patients.
